Cerus (CERS) investor relations material

Company overview and strategic focus

• Focused on transforming transfusion medicine by making pathogen-reduced blood components a global standard of care.

• Founded in the early 1990s to address blood safety during HIV and hepatitis epidemics.

• Products are now commercialized in over 40 countries, with ongoing expansion into untapped markets.

• Mission-driven to ensure real-time, citywide access to safe blood products.

Financial performance and outlook

• Achieved 16% year-over-year growth and raised revenue guidance to $200–203M.

• IFC product guidance nearly doubled, expected to be a key midterm growth driver.

• Operating cash flow expected to be positive for the full year, with improved margins and leverage on SG&A and R&D.

• Five consecutive quarters of positive adjusted EBITDA, aiming for a second year of positive results.

• $65M term debt starts amortizing in April, with options to extend and $80M cash on hand.

Product innovation and market expansion

• IFC (Intercept Fibrinogen Complex) offers rapid, pathogen-reduced fibrinogen for major bleeding events, with a five-day shelf life and reduced waste.

• IFC is primarily focused on the US, with future plans for UK, Asia Pacific, and other markets.

• INTERCEPT platelets have 65–70% US penetration, with further growth expected as new guidelines and devices are adopted.

• Next-gen LED illuminator developed for improved efficiency, throughput, and IP protection.

• Red blood cell product under regulatory review in Europe, with US phase 3 trials ongoing; initial commercialization to target irradiated red cells.